Patents by Inventor Dawei BU

Dawei BU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MONOCLONAL ANTIBODIES AGAINST ENDOTROPHIN AND THE USE THEREOF
    Publication number: 20250270312
    Abstract: Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alpha3 chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient.
    Type: Application
    Filed: May 7, 2025
    Publication date: August 28, 2025
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Ningyan ZHANG, Dawei BU, Zhiqiang AN, Hui DENG, Philipp E. SCHERER
  • Monoclonal antibodies against endotrophin and the use thereof
    Patent number: 12331110
    Abstract: Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alphas chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: June 17, 2025
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Ningyan Zhang, Dawei Bu, Zhiqiang An, Hui Deng, Philipp E. Scherer
  • MONOCLONAL ANTIBODIES AGAINST ENDOTROPHIN AND THE USE THEREOF
    Publication number: 20220056124
    Abstract: Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alphas chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient.
    Type: Application
    Filed: September 5, 2019
    Publication date: February 24, 2022
    Inventors: Ningyan ZHANG, Dawei BU, Zhiqiang AN, Hui DENG, Philipp E. SCHERER